Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00062504
Recruitment Status : Terminated
First Posted : June 12, 2003
Last Update Posted : May 23, 2011
National Cancer Institute (NCI)
Information provided by:
Teva Pharmaceutical Industries

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : January 2006
  Actual Study Completion Date : April 2006